克唑替尼诱发的胰腺假性囊肿：一种新的不良事件。
Crizotinib-induced pancreatic pseudocyst: a novel adverse event.
作者信息
Ishida Hiroo, Ichikawa Wataru, Sasaki Yasutsuna
机构信息
Division of Medical Oncology, Department of Medicine, Showa University, Tokyo, Japan.
Division of Medical Oncology, Showa University Fujigaoka Hospital, Kanagawa, Japan.
出版信息
BMJ Case Rep. 2015 Sep 8;2015:bcr2015211556. doi: 10.1136/bcr-2015-211556.
Crizotinib is a tyrosine kinase inhibitor that demonstrates a dramatic tumour response in patients with advanced non-small cell lung cancers harbouring anaplastic lymphoma kinase (ALK) rearrangement. The pancreatic cyst has never been reported in patients who received crizotinib, whereas crizotinib-induced renal cysts developed in 4% of patients who were enrolled in clinical trials. We present the case of a 54-year-old man who was diagnosed with non-small cell lung cancer harbouring ALK rearrangement. After the start of treatment with crizotinib, we accidentally encountered the pancreatic pseudocyst without abdominal symptom and elevated serum pancreatic enzymes. In this report, we describe a case of pancreatic pseudocyst that appeared after starting treatment with crizotinib and regressed after treatment withdrawal.
克唑替尼是一种酪氨酸激酶抑制剂，对携带间变性淋巴瘤激酶（ALK）重排的晚期非小细胞肺癌患者具有显著的肿瘤反应。接受克唑替尼治疗的患者中从未有胰腺囊肿的报道，而在参与临床试验的患者中，4%出现了克唑替尼诱导的肾囊肿。我们报告了一例54岁男性，诊断为携带ALK重排的非小细胞肺癌。在开始使用克唑替尼治疗后，我们意外发现了无症状且血清胰腺酶未升高的胰腺假性囊肿。在本报告中，我们描述了一例在开始使用克唑替尼治疗后出现并在停药后消退的胰腺假性囊肿病例。
Zotero 插件